Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.94
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2
Open
83.94
Bid (Size)
83.55 (1)
Ask (Size)
84.04 (1)
Prev. Close
83.94
Today's Range
83.94 - 83.94
52wk Range
62.07 - 87.86
Shares Outstanding
1,253,809,440
Dividend Yield
3.57%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Gilead Sciences Unusual Options Activity For September 20
September 20, 2024
Via
Benzinga
Performance
YTD
+0.84%
+0.84%
1 Month
+9.41%
+9.41%
3 Month
+18.68%
+18.68%
6 Month
+15.65%
+15.65%
1 Year
+12.17%
+12.17%
More News
Read More
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 20, 2024
Via
Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
Via
The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
September 13, 2024
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
What the Options Market Tells Us About Gilead Sciences
September 12, 2024
Via
Benzinga
Peering Into Gilead Sciences's Recent Short Interest
September 06, 2024
Via
Benzinga
Unveiling 10 Analyst Insights On Gilead Sciences
September 04, 2024
Via
Benzinga
Why Gilead Sciences Stock Thrashed the Market Today
September 12, 2024
Via
The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
September 12, 2024
Via
Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
September 12, 2024
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
September 12, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
September 03, 2024
Via
Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
August 27, 2024
Via
Benzinga
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
September 10, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Four Stocks To Watch This Week - Monday, Sept 9
September 09, 2024
Via
Talk Markets
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
September 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
August 22, 2024
Via
Benzinga
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
Via
Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Gilead Sciences to Present at Upcoming Investor Conferences
August 21, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.